Search company, investor...



Series A | Alive

Total Raised


Last Raised

$20M | 13 yrs ago

About Altheos

Altheos, Inc. is an early-stage biopharmaceutical company focused on the identification and development of promising well-differentiated novel small molecule drugs for unmet medical needs. Altheos, Inc. was co-founded in 2009 by two experienced pharmaceutical drug development executives and entrepreneurs, Henry H. Hsu, M.D. and M. (Ken) Kengatharan, Ph.D. The company is headquartered in South San Francisco, California.

Headquarters Location

400 Oyster Point Boulevard

South San Francisco, California, 94080,

United States


Missing: Altheos's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Altheos's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Altheos

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Altheos is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Altheos Frequently Asked Questions (FAQ)

  • Where is Altheos's headquarters?

    Altheos's headquarters is located at 400 Oyster Point Boulevard, South San Francisco.

  • What is Altheos's latest funding round?

    Altheos's latest funding round is Series A.

  • How much did Altheos raise?

    Altheos raised a total of $20M.

  • Who are the investors of Altheos?

    Investors of Altheos include Canaan Partners, Novo Holdings, Bay City Capital, Life Science Angels and Atheneos Ventures.

  • Who are Altheos's competitors?

    Competitors of Altheos include Adamas Pharmaceuticals, BioCardia, VistaGen, KBI Biopharma, iPierian and 12 more.

Compare Altheos to Competitors

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Epiphany Biosciences

Epiphany Biosciences is focused on advancing new therapies for infectious disease. The founders include Fred Volinsky MD, Robert Gallo MD, David Myles Ph.D and Barry Selick Ph.D. Epiphany is located in San Francisco, California.

Tempo Pharmaceuticals

Tempo Pharmaceuticals is developing a nanoparticle technology designed to improve the safety and efficacy of marketed and development-stage drugs.


The company are developing siRNA drugs targeting a control factor for HIF (hypoxia-inducible factor), which is one of the main factors involved in angiogenesis. The company have found that siRNA can promote angiogenesis by inducing expression of several angiogenic factors simultaneously by preventing breakdown of HIF inside the cell. It is therefore expected that delivery of siRNA to disease-affected sites can efficiently induce angiogenesis, leading to a in treatment for obstructive arteriosclerosis.

Altea Therapeutics

Altea Therapeutics is using advanced delivery across the skin that aim to improve the efficacy, safety and compliance of drugs and vaccines.

Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.